Source: Annual Congress 2011 - Innovative diagnostic methods for lung cancer
Disease area: Interstitial lung diseases, Thoracic oncology

Abstract

There are several factors involved in angiogenesis, not tested yet, whose role is not clear in patients with lung cancer. Our pilot study was carried out to analyze the serum IL-20, Galectin 3, IL-29 and IL-33 (ELISA) in patients with non-small cell lung cancer (45 NSCLC) before chemotherapy, 15 sarcoidosis (BBS), 8 hypersensitivity pneumonitis (HP) and 15 healthy controls (H). Serum concentration of IL-20 was highest in NSCLC, lower in BBS and H, and lowest in HP (45,1±2 vs 41,88±11 vs 40±5,5 vs 36,09±2,7 pg/ml; p=0,01). The levels of Galectin 3 was highest in HP, lower in BBS, NSCLC, lowest in H (2,5±0,3 vs 1,2 ±0,4 vs 0,9±0,5 vs 0,8 ± 0,1 pg/ml; p=0,03). The highest level of IL-29 was in HP, lower in NSCLC and H , the lowest in BBS (85,70±12 vs 53,65±2,8 vs 45,22 ±2,5 vs 38,68±1,7 pg/ml; p=0,003). Serum levels of IL-33 was lowest in H, higher in NSCLC and BBS, the highest in HP (3,57±0,9 vs 4,1±0,5 vs 5,56±3,7 vs 7,24±1,5 pg/ml; p= 0,02). Serum levels of IL-29 and IL-33 were lower in patients with metastases of NSCLC (IL-29: 85,19±18 vs 48,33 pg/ml; p=0,03; IL-33: 4,54±4,2 vs 3,61 ±2,1 pg/ml; p=0,04). There were no significant differences in serum IL-20, Galectin 3, IL-29 and IL-33 in relation to a response to a therapy.A correlations were found between IL-33 and Galectin 3 concentrations (R= 0.60). Summing up, serum concentrations of IL-20, Galectin 3, IL-29 and IL-33 were higher in patients with NSCLC than in healthy people. Their clinical usefulness in the diagnosis of cancer seems to be weak, but this requires further investigation.

Rating:

Share or cite this content

Citations should be made in the following way:
W. Naumnik, M. Ossolinska, K. Niewiarowska, E. Chyczewska (Bialystok, Poland). Late-breaking abstract: Serum concentrations of new factors (IL-20, galectin 3, IL-29 and IL-33) involved in angiogenesis in patients with advanced non-small cell lung cancer (NSCLC). Eur Respir J 2011; 38: Suppl. 55, 4500

Member's Comments

No comment yet.

Related content which might interest you: LATE-BREAKING ABSTRACT: Expression of macrophage migration inhibitory factor (MIF) in the serum and lung tissues in patients with non-small cell lung cancer (NSCLC) Source: Annual Congress 2012 - Prognosis of lung cancer Year: 2012 Serum levels of interleukin 8 and plasma levels of osteopontin in patients with non-small cell lung cancer during chemotherapy Source: Annual Congress 2011 - Instructive clinical aspects of lung cancer Year: 2011 Serum level of GFBP-1 and IGFBP-6 in patients with non-small cell lung cancer (NSCLC) during chemotherapy Source: Annual Congress 2009 - Biological and clinical markers in lung cancer Year: 2009 Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer (NSCLC) treated with nivolumab (nivo). Source: International Congress 2018 – Lung cancer: new aspects in diagnosis and management Year: 2018 The role of TNF-α and IL-6 in the development of cancer anorexia - cachexia syndrome (CACS) in non-small cell lung cancer (NSCLC) Source: Eur Respir J 2004; 24: Suppl. 48, 673s Year: 2004 Serum level of IGF-I and IGF-II in patients with non-small cell lung cancer (NSCLC) during chemotherapy Source: Eur Respir J 2004; 24: Suppl. 48, 82s Year: 2004 Is it possible to predict response to cancer chemotherapy (CTh) in patients (pts) with non-small cell lung cancer (NSCLC) on the basis of serum CYFRA 21-1 level (sCY21)? Source: Eur Respir J 2002; 20: Suppl. 38, 74s Year: 2002 TNFα as a prognostic factor in surgically treated non-small cell lung carcinomas Source: Annual Congress 2005 - Management of lung cancer: clinical problems Year: 2005 Pre-operative levels of serum vascular endothelial growth factor A (VEGF-A), C (VEGF-C) and D (VEGF-D) in non-small cell lung cancer (NSCLC). Preliminary report Source: Annual Congress 2008 - Management, quality aspects and prognosis in thoracic oncology Year: 2008 Increased vascular-endothelial growth factor a (VEGF-A) expression and response to angiogenesis inhibitor erlotinib in non-small-cell lung cancer (NSCLC) – hint for a new predictive marker? Source: Annual Congress 2007 - Therapeutic approaches in thoracic oncology Year: 2007 Efficacy of Afatinib, Erlotinib, and Gefitinib on epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) patients with brain metastasis: a network meta-analysis Source: International Congress 2018 – Lung cancer: modern therapies and beyond Year: 2018 Macrophage expression of interleukin-10 is a prognostic factor in nonsmall cell lung cancer Source: Eur Respir J 2007; 30: 627-632 Year: 2007 Response to cancer chemotherapy (CTh) in patients (pts) with non-small cell lung cancer (NSCLC) according to their serum levels of chosen tumor markers (CYFRA 21-1 (CY21), CEA and NSE) Source: Eur Respir J 2001; 18: Suppl. 33, 377s Year: 2001 Plasma leptin levels in nonsmall cell lung carcinoma (NSCLC) patients at the time of the diagnosis Source: Eur Respir J 2001; 18: Suppl. 33, 65s Year: 2001 The neoadjuvant therapy of NSCLC down-regulates serum levels of growth factors (VEGF, bFGF, TGF-beta) with no effect on apoptosis (CD95L) and local tumour invasiveness markers (TIMP-1) Source: Eur Respir J 2006; 28: Suppl. 50, 386s Year: 2006 Is Cyfra 21-1 serum level predictive for the type of response to treatment or survival in locally advanced and metastatic non-small cell lung cancer (NSCLC)? Source: Eur Respir J 2004; 24: Suppl. 48, 76s Year: 2004 Predicting activity of EGFR (epidermal growth factor receptor) inhibitors in diffuse bronchiolo-alveolar carcinoma or so-called pneumonic adenocarcinoma Source: Annual Congress 2006 - Bronchiolo-alveolar carcinoma Year: 2006 Heterogeneous reactivity of ICAM-1 on alveolar macrophages (AMs) in patients with non-small cell lung cancer (NSCLC) Source: Eur Respir J 2003; 22: Suppl. 45, 256s Year: 2003 Role of EBUS-TBNA in the study of PD-L1 expression in patients with non-small cell lung cancer (NSCLC) Source: Virtual Congress 2020 – Endobronchial ultrasound: from rookie to pro Year: 2020 Role of chemokines in resectable non-small cell lung cancer (NSCLC) Source: International Congress 2019 – Biology and prognosis of lung cancer Year: 2019